Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | RARB | P10826 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1023839 | 0.96 | TP53 (0.70) | TP53TSHRPLA2G4BL3MBTL1RARB | |
| SCHEMBL10045771 | 0.95 | TP53 (0.73) | TP53TSHRPLA2G4BRARBGAA | |
| SCHEMBL2399489 | 0.95 | TP53 (0.73) | TP53TSHRPLA2G4BRARBGAA | |
| SCHEMBL1019300 | 0.95 | TP53 (0.73) | TP53TSHRPLA2G4BRARBGAA | |
| SCHEMBL8728342 | 0.95 | TP53 (0.73) | TP53TSHRPLA2G4BRARBGAA | |
| SCHEMBL5206359 | 0.95 | TP53 (0.73) | TP53TSHRPLA2G4BRARBGAA | |
| SCHEMBL1022325 | 0.95 | TP53 (0.73) | TP53TSHRPLA2G4BRARBGAA | |
| SCHEMBL9161795 | 0.95 | TP53 (0.73) | TP53TSHRPLA2G4BRARBGAA | |
| SCHEMBL4209056 | 0.95 | TP53 (0.73) | TP53TSHRPLA2G4BRARBGAA | |
| SCHEMBL7721896 | 0.95 | TP53 (0.58) | TP53TSHRPLA2G4BL3MBTL1RARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6214990-B1 | 2,9-BIS(4-METHOXYBENZOYLOXY),3,10-DIMETHOXY,6,13-DICHLORO -PHENODIOXAZINE, FOR EXAMPLE; DYE HAS NARROW LIGHT ABORPTION BAND AND HIGH DICHROIC RATIO | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-04-10 | — | — | US | claimed |
| JP-1311098-A | — | — | None | — | — | JP | disclosed |
| US-12281108-B2 | Pyrrolidinone derivatives as formyl peptide 2 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2024235876-A1 | PYRIDOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | FERNANDEZ CAPETILLO OSCAR (SE) | 2024-11-21 | — | — | WO | disclosed |
| CN-118271331-A | Gelsemin derivatives, synthesis method and application thereof in inhibiting tumor cell proliferation | 赣江中药创新中心 | 2024-07-02 | — | — | CN | disclosed |
| CN-113166134-B | Pyrrolidone derivatives as formyl peptide 2 receptor agonists | 百时美施贵宝公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-3887366-B1 | PYRROLIDINONE DERIVATIVES AS FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-27 | — | — | EP | disclosed |
| CN-111320564-B | Room temperature phosphorescent material with excitation wavelength dependence and preparation method and application thereof | 湖州师范学院 | 2023-05-23 | — | — | CN | disclosed |
| US-20220002281-A1 | PYRROLIDINONE DERIVATIVES AS FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-01-06 | — | — | US | disclosed |
| US-20220002281-A1 | PYRROLIDINONE DERIVATIVES AS FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-01-06 | — | — | US | disclosed |
| EP-0041711-A1 | 6-Chloro- or 6-bromo-1,2-dihydro-3H-pyrrolo(1,2-a)-pyrrole-1-carboxylic acids and derivatives thereof, process for their production and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1981-12-16 | — | — | EP | disclosed |
| US-4207327-A | N-(4-Pyrazolidinyl)benzamides and their amino precursors | A. H. ROBINS COMPANY, INC. (US) | 1980-06-10 | — | — | US | disclosed |
| US-4192677-A | ELECTROGRAPHIC CHARGE TRANSFER COMPOUNDS | RICOH CO., LTD. (JP) | 1980-03-11 | — | — | US | disclosed |
| US-4182881-A | N-[Diaminophosphinyl]arylcarboxamides | MORTON-NORWICH PRODUCTS, INC. (US) | 1980-01-08 | — | — | US | disclosed |
| US-4141729-A | 1,3,4-Oxadiazole derivatives and electrophotographic plates containing same | RICOH COMPANY, LTD. (JP) | 1979-02-27 | — | — | US | disclosed |
| US-4136100-A | BLUE-VIOLET TO GREEN-BLUE DYEINGS ON CELLULOSE TEXTILES | BASF AKTIENGESELLSCHAFT (DE) | 1979-01-23 | — | — | US | disclosed |
| US-4024153-A | ULTRAVIOLET STABILIZERS | EASTMAN KODAK COMPANY (US) | 1977-05-17 | — | — | US | disclosed |
| US-4009208-A | N,N'-HEPTAMETHYLENEBIS(4-METHOXYBENZAMIDE) | STERLING DRUG INC. (US) | 1977-02-22 | — | — | US | disclosed |
| US-4001426-A | HAVING CORONARY VASODILATOR ACTIVITY | SMITHKLINE CORPORATION (US) | 1977-01-04 | — | — | US | disclosed |
| US-3954706-A | Polychromophoric benzotriazole ultraviolet stabilizers for organic compositions | EASTMAN KODAK COMPANY (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281108-B2 | Pyrrolidinone derivatives as formyl peptide 2 receptor agonists | FPR1, FPR2, FPR3 | TP53 4367/4885TSHR 747/4885PLA2G4B 310/4885 |
| US-20220002281-A1 | PYRROLIDINONE DERIVATIVES AS FORMYL PEPTIDE 2 RECEPTOR AGONISTS | FPR1, FPR2, FPR3 | TP53 4367/4885TSHR 747/4885PLA2G4B 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.